Licensing agreement will integrate ALZpath’s pTau217 antibody into Siemens’ Atellica analyzer test menu for IVD Alzheimer’s diagnostics.
ALZpath Inc has signed a licensing agreement with Siemens Healthineers to integrate its proprietary pTau217 antibody into the development of a new in vitro diagnostic assay for Alzheimer’s disease testing on Siemens’ Atellica immunoassay systems.
The partnership will add the pTau217 assay to Siemens Healthineers’ expanding menu of IVD tests for Alzheimer’s disease, enabling clinical laboratories to perform blood-based testing for the neurodegenerative condition using a simple blood draw.
ALZpath’s pTau217 antibody has demonstrated performance comparable to PET imaging and cerebrospinal fluid testing for detecting Alzheimer’s disease pathology, according to the company. The antibody is supported by clinical evidence from more than 90 peer-reviewed studies.
“This agreement supports ALZpath’s mission to democratize access to early and accurate Alzheimer’s disease testing,” says Mike Banville, chief executive officer of ALZpath, in a release. “By enabling Siemens Healthineers to integrate our pTau217 antibody across its expansive immunoassay testing footprint, we are expanding global access to timely diagnosis as new therapies become available to patients.”
Addressing Growing Diagnostic Needs
The collaboration addresses increasing demand for scalable diagnostic tools as disease-modifying therapies for Alzheimer’s become more widely available. Blood-based testing offers advantages over traditional diagnostic methods by providing a more accessible and less invasive alternative to PET scans and lumbar punctures for cerebrospinal fluid collection.
Siemens Healthineers’ Atellica analyzers are designed to maximize assay precision while providing high throughput capabilities for faster patient results. The integrated immunoassay and clinical chemistry systems are used in clinical laboratories globally across various sizes and settings.
“Collaboration drives innovation and advances patient care. The sooner we detect degenerative diseases, the more time clinicians, patients, and families have to prepare—and the more impactful disease modifying therapies can be,” says Dirk Heckel, chief technology officer and head of research, development, and innovation for diagnostics at Siemens Healthineers, in a release.
Expanding Market Presence
The partnership represents another licensing agreement for ALZpath, which has established collaborations with multiple industry partners including Roche, Beckman Coulter, Bio-techne, Alamar Biosciences, and Quanterix. The company also works with laboratories such as Neurocode to expand global access to early Alzheimer’s detection.
The pTau217 assay for Siemens’ Atellica systems is currently under development, and future availability cannot be guaranteed, according to the companies.
ID 118882148 © Tampatra1 | Dreamstime.com
